Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis.
Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis. Oncotarget. 2018 Jun 19;9(47):28445-28455 Authors: Maracle CX, Jeucken KCM, Helder B, van Gulik TM, Steins A, van Laarhoven HWM, Tas SW Abstract Angiogenesis is essential for colorectal cancer (CRC) progression, as demonstrated by the beneficial clinical effects of therapeutics inhibiting VEGF signaling. However, alternative mechanisms of neovascularization can develop, resulting in treatment failure. Previously we demonstrated NF-κB-inducing kinase (NIK) contributes to pathological angiogenesis. Here, we investigate NIK as a therapeutic target in endothelial cells (EC) in CRC. To determine NIK expression levels in CRC tissues, we immunostained both primary colorectal tumors and tumors metastasized to the liver. Additionally, a 3D tumor-stromal cell interaction model was developed including EC, fibroblasts and CRC cells to study tumor angiogenesis. This model tested efficacy of NIK-targeting siRNA (siNIK) in EC alone or in combination with the anti-VEGF antibody, bevacizumab. Both primary CRC and liver metastases contained blood vessels expressing NIK. In patients receiving chemotherapy plus bevacizumab, immature NIK+ vessels (p
AbstractAll colon cancer patients with lymph node (LN) positive disease are treated with chemotherapy. Patients with node negative disease are usually cured by surgery alone. Yet about 20% of patients develop recurrence within 5 years despite node negative status. This may often be the result of missed micrometastases by conventional examination. Sentinel lymph node (SLN) mapping was developed to find those nodes detected by blue dye which was ultrastaged to detect micrometastases. Consecutive patients, underwent SLN mapp ing with the blue dye with success rate of 99.2%. Average number of LN was 18.3, average number ...
ConclusionThese results show promise for larger studies that could result in more personalized treatment protocols for CRC patients.
In conclusion, this large prospective cohort study showed a high rate of venous thromboembolism in patients with a solid tumor and implanted port. Risk factors for catheter-related thrombosis differed from those for venous thromboembolism not catheter-related. This trial was registered at www.clinicaltrials.gov as #NCT02025894.
AbstractToxicities can affect cancer patients ’ quality of life resulting in poor adherence to adjuvant chemotherapy (AC). While previous studies have explored the prevalence of toxicities following AC, few have examined the associations of baseline characteristics, such as age, sex, and performance status, with toxicity outcomes. In this stu dy, we reviewed a cohort of 371 colorectal cancer patients treated with adjuvant monotherapy (capecitabine ) or combination therapy (FOLFOX or CAPOX) within 12 weeks of curative resection, and determined the associations between baseline characteristics and toxicity outcome...
ConclusionsThis case highlights the importance of recognizing gastrointestinal complications following chemotherapy and the need to be aware of the possibility of bowel perforation. Prompt surgical review and intervention must be requested in patients with acute abdominal pain and persistent gastrointestinal symptoms such as diarrhea and vomiting.
Authors: Oweira H, Abdel-Rahman O, Giryes A, Mannhart M, Decker M Abstract BACKGROUND: Time to start adjuvant therapy has been shown to be an important determinant of survival following curative resection of colorectal cancer. Time to start systemic therapy following diagnosis of metastatic colorectal cancer (mCRC) needs to be additionally studied and assessed. METHODS: This is a pooled analysis of the raw data of the comparator arms of two randomized studies (NCT00272051; NCT00305188). Univariate and Multivariate analysis of predictors of overall and progression-free survival was conducted through Cox regressi...
The chemotherapy dripped through a catheter in his chest. Cancer patient Robert Goodman had burned through his paid sick days while undergoing surgery and chemotherapy for colon cancer.
The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
The objective of this review is to present insights into pharmacotherapeutic techniques, which can be used for transdermal delivery of anticancer agents through skin due to its potential to create a new frontier in treatment of cancer. PMID: 30095010 [PubMed - as supplied by publisher]
International Journal of Cancer, EarlyView.